Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PTK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTGDR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PTGDR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PRCD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRCD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PRAME Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
18 September 2026
A Biology Modality MCP review of PRAME sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PPARGC1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARGC1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PPARD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PPARD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PNMA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PNMA3 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PNMA2 Biologics Sequence Review Report 2026: Paraneoplastic antigen Ma2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PNMA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PLAUR Biologics Sequence Review Report 2026: Urokinase plasminogen activator surface receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PLAUR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PGF Biologics Sequence Review Report 2026: Placenta growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PEX5 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 1 receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PEX5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
874
875
876
877
878
>>
2926
>